Silexion’s Stock Tanks as $1.8M Warrant Raise Fuels SIL-204 Phase 2/3 Push
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company headquartered in Modiin, Israel. The company focuses on RNA interference therapies for KRAS-driven solid tumors. Its lead candidate, SIL-204, is an extended-release small interfering RNA (siRNA) formulation currently under investigation as a first-line treatment in combination with standard-of-care chemotherapy for locally advanced pancreatic cancer.
Corporate Structure
Silexion operates as a privately held entity with 11–50 employees, conducting research and development activities in Israel. Manufacturing partnerships include LGC Axolabs (Petaluma, California) for GMP-compliant siRNA production and Evonik Corporation (Birmingham, Alabama) for the scale-up of extended-release formulations. The management team has experience in oncology drug development, finance, and regulatory compliance.
Biotechnology by Sangharsh Lohakare
Recent Developments and News
- In July 2025, Silexion announced the exercise of warrants, generating $1.8 million in gross proceeds to support ongoing clinical programs.
- In July 2025, preclinical results reported up to 97 percent inhibition of cancer cell growth across various KRAS mutations, including data against previously untested variants.
- Also in July 2025, the company reported positive efficacy of SIL-204 in human lung cancer cell lines and announced plans for a Phase 2/3 trial in pancreatic cancer patients with KRAS G12D and G12V mutations.
- A collaboration agreement with Catalent for advanced siRNA formulation development and clinical manufacturing was executed in July 2025.
- On July 29, 2025, Silexion completed a 1-for-15 reverse share split prior to the opening of trading.
- On July 31, 2025, the company filed a definitive proxy statement (Form DEF 14A) proposing to increase its authorized share capital from $20,000 to $121,500 to ensure compliance with Nasdaq Listing Rule 5550(b)(1).
Financial and Strategic Analysis
As of August 1, 2025, SLXN shares closed at $9.00, representing a 39.76 percent decrease from the prior trading day, with a trading volume of 125,373 shares. Reports indicate a market capitalization of approximately $8.66 million (Yahoo Finance) or $5.2 million (CNBC), which reflects variations in share counts and pricing sources. Key financial metrics include:
| Metric | Value |
|---|---|
| Share Price (August 1, 2025) | $9.00 (–39.76%) |
| 52-Week Range | $3.11 – $203.37 |
| Market Capitalization | $8.66 million |
| Trailing EPS (TTM) | –29.00 |
| Net Income (TTM) | –$16.44 million |
| Total Cash (MRQ) | $1.19 million |
| Debt/Equity (MRQ) | 115.74% |
| Beta (5Y Monthly) | 0.05 |
The company’s cash position and recent $1.8 million from warrant proceeds are intended to support key clinical milestones. Additionally, the proposed increase in authorized share capital—subject to a shareholder vote on August 12, 2025—and the requirement to achieve $2.5 million in shareholders’ equity by September 19, 2025, indicate the need for additional financing to maintain listing on Nasdaq and to fund ongoing clinical trials.
Market Position and Industry Context
Silexion operates within the oncology biotechnology sector, which is characterized by significant research expenditures, regulatory challenges, and competitive pressures in KRAS-targeted therapies. The company does not yet have marketed products and has a focused pipeline on solid tumors, facing common clinical and financial challenges faced by small-cap biotech firms. SLXN's low trading volume and the wide 52-week price range underscore investor interest that is largely influenced by pipeline developments rather than actual revenues.
tl;dr
SLXN shares decreased by 39.76% to $9.00 on August 1, 2025, amid funding pressures. The company raised $1.8 million through warrant exercises in July and is seeking shareholder approval on August 12 to increase its authorized share capital before a September 19 Nasdaq equity deadline. Preclinical data indicating up to 97% tumor inhibition and plans for a Phase 2/3 trial for SIL-204 represent upcoming catalysts for the company’s next funding round and clinical milestones.